Allspring Global Investments Holdings LLC Acquires 12,882 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Allspring Global Investments Holdings LLC lifted its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 80.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 28,990 shares of the company’s stock after acquiring an additional 12,882 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Teva Pharmaceutical Industries were worth $303,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 184,642.3% in the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 27,711,340 shares of the company’s stock worth $282,656,000 after acquiring an additional 27,696,340 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 14.4% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 27,059,540 shares of the company’s stock worth $276,000,000 after acquiring an additional 3,413,100 shares during the last quarter. Rubric Capital Management LP lifted its holdings in shares of Teva Pharmaceutical Industries by 1.5% in the 3rd quarter. Rubric Capital Management LP now owns 19,000,000 shares of the company’s stock worth $193,800,000 after acquiring an additional 281,638 shares during the last quarter. AustralianSuper Pty Ltd lifted its holdings in shares of Teva Pharmaceutical Industries by 18.8% in the 4th quarter. AustralianSuper Pty Ltd now owns 9,039,070 shares of the company’s stock worth $94,368,000 after acquiring an additional 1,431,671 shares during the last quarter. Finally, Sound Shore Management Inc CT bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth approximately $80,791,000. 54.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CAO Amir Weiss sold 31,766 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $12.37, for a total value of $392,945.42. Following the completion of the transaction, the chief accounting officer now directly owns 10,676 shares in the company, valued at approximately $132,062.12. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CAO Amir Weiss sold 31,766 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $12.37, for a total value of $392,945.42. Following the completion of the transaction, the chief accounting officer now directly owns 10,676 shares in the company, valued at approximately $132,062.12. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Eric Drape sold 173,261 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $13.05, for a total transaction of $2,261,056.05. Following the sale, the vice president now directly owns 1 shares in the company, valued at $13.05. The disclosure for this sale can be found here. Insiders sold a total of 390,738 shares of company stock worth $5,132,766 in the last three months. 0.55% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on TEVA shares. The Goldman Sachs Group lifted their target price on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a “neutral” rating in a research note on Monday, February 5th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 1st. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price target for the company in a report on Friday, March 8th. Piper Sandler upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and upped their price target for the company from $12.00 to $19.00 in a report on Monday, February 12th. Finally, Jefferies Financial Group upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and upped their price target for the company from $10.00 to $14.00 in a report on Tuesday, January 23rd. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $13.78.

Teva Pharmaceutical Industries Stock Up 4.2 %

Shares of NYSE TEVA opened at $13.80 on Friday. The company has a current ratio of 1.02, a quick ratio of 0.69 and a debt-to-equity ratio of 2.23. Teva Pharmaceutical Industries Limited has a 12 month low of $7.09 and a 12 month high of $14.47. The firm has a market capitalization of $15.47 billion, a PE ratio of -29.36, a price-to-earnings-growth ratio of 1.56 and a beta of 1.05. The firm has a fifty day simple moving average of $13.51 and a two-hundred day simple moving average of $11.39.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 31st. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.25. The company had revenue of $4.46 billion during the quarter, compared to analyst estimates of $3.97 billion. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%. Equities analysts expect that Teva Pharmaceutical Industries Limited will post 2.28 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.